Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

NCT02616848 is registered in ClinicalTrials.gov with Istituti Ospitalieri di Cremona as lead sponsor.

NCT NCT02616848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02616848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Lead sponsor
Istituti Ospitalieri di Cremona
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2015
Completion date
Not reported
Enrollment
1 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer